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Abstract
Background: Optic nerve sheath meningiomas account for only 2 % of orbital lesions and 42 % of optic nerve
tumors. Diagnosis remains difficult because histologic confirmation carries a high risk of visual loss. Therefore, a less
invasive and specific diagnostic method for differentiating optic nerve sheath meningiomas from other optic nerve
lesions is needed to overcome the limitations of computed tomography and magnetic resonance imaging, and
make the best individualized treatment decision. This case is a good illustration of the clinical and imaging
difficulties inherent in this rare tumor, which may be hard to differentiate from other causes.
Case presentation: A 51-year-old Caucasian woman developed a central scotoma, visual loss, and abnormal visual
evoked potentials. The first magnetic resonance imaging scan classified the optic nerve damage as retrobulbar
optic neuritis. After magnetic resonance imaging follow-up at 3 months, a negative lumbar puncture and biological
workup, and clinical worsening, an optic nerve sheath meningioma was suspected. We confirmed this diagnosis
with 111In-pentetreotide single-photon emission computed tomography, which is able to bind with very high
affinity to somatostatin receptor subtype 2 expressed on meningiomas.
Conclusions: In the diagnosis of optic nerve sheath meningiomas, [111In]-pentetreotide single-photon emission
computed tomography-fused magnetic resonance imaging is a valuable additional tool, optimizing the diagnosis
and obviating the need for a more invasive procedure.
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Background
Optic nerve sheath meningiomas (ONSMs) account for
2 % of orbital lesions and are the second most common
optic nerve tumors, after optic nerve gliomas [1–4].
Clinically, optic nerve tumors closely mimic optic neur-
itis with painless unilateral vision impairment [2, 5].
Diagnosis remains difficult because histologic confirm-
ation carries a high risk of visual loss. Therefore, a less
invasive and specific diagnostic method for differentiat-
ing ONSMs from other optic nerve tumors is crucial for
individualized treatment decisions. Meningiomas in-
tensely express the somatostatin receptors [6–13], and
receptor-negative cases are extremely rare [8]. Since
somatostatin receptor scintigraphy has applications in
the differential diagnosis between ONSMs and other or-
bital lesions, magnetic resonance imaging (MRI) is par-
ticularly valuable for evaluation of orbital neoplasms
because it provides critical anatomic information on the
ocular structures involved, perineural spread and intra-
cranial extension [3].
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We present a case of ONSM diagnosed using [111In]-
pentetreotide single-photon emission computed tomog-
raphy/computed tomography (SPECT/CT) in a patient
initially followed for a diagnosis of optic neuritis.
Case presentation
A 51-year-old Caucasian woman initially consulted for
right visual loss (2/10, with corrective lenses) and central
scotoma demonstrated with perimetry. Visual evoked
potentials confirmed the altered conduction of the right
optic nerve. In the absence of any other obvious neuro-
logic symptoms and signs, optic neuritis was suspected.
An initial MRI scan showed right tortuous optic nerve
enlargement with a peripherally increased signal on fluid-
attenuated inversion recovery (Fig. 1b) and on coronal
T2-weighted fat-suppressed (Fig. 1f) sequences. Therefore,
uniform contrast enhancement (Fig. 1a and e) affected the
last third of the nerve.
Three months later, follow-up MRI demonstrated the
persistent signal abnormalities on MRI. A comprehensive
biological workup including lumbar puncture – initially
refused by the patient – showed no abnormal results, and
an ONSM was suspected.
SPECT/CT was performed 24 h after injection of 180
MBq [111In]-pentetreotide and showed an intense uptake
in the last third of the intraorbital right optic nerve
(Fig. 1d and h) corresponding to the contrast enhance-
ment on the MRI scan. After this confirmation, she was
referred to the radiotherapy center for stereotaxic radio-
therapy. A treatment consisting in 30 sessions of stereo-
taxic radiotherapy was planned. Our patient received a
total of 54 Gy by photons of 6 MeV (1.8 Gy per session),
which was well tolerated. The 1-year clinical follow-up
was positive with disappearance of the Marcus Gunn
pupil sign, better visual acuity (7/10, with corrective
lenses), and stability on MRI imaging.
Discussion
Although meningiomas are common intracranial tu-
mors, ONSMs as a specific subset are infrequent,
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Fig. 1 Multimodal imaging: matched transverse, postcontrast spin-echo T1-weighted (a), and fluid-attenuated inversion recovery (b) 1.5-T MRI scans,
fused MRI/SPECT (c) and 111In-pentetreotide SPECT images (d). Transverse postcontrast gradient echo T1-weighted MRI scan (e) showing the location
of coronal slices, and three-level coronal T2-weighted fat-suppressed MRI scan (f), fused MRI/SPECT image (g) and [111In]-pentetreotide SPECT image
(h). MRI scan showed right tortuous optic nerve enlargement (b, dotted arrow), with a peripherally increased signal on fluid-attenuated inversion
recovery (b, dotted arrow) and on coronal T2-weighted fat-suppressed sequences (f, dotted arrow). Therefore, uniform contrast enhancement
(a and e, solid arrows) affected the last third of the nerve corresponding to an intense [111In]-pentetreotide uptake (d and h). The asterisk (*) shows the
physiological uptake of [111In]-pentetreotide in the pituitary (c and d)
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accounting for only 1–2 % of all meningiomas [14].
Since morphological imaging techniques have their limi-
tations in differentiating meningiomas from other tu-
mors of the optic pathway [3, 6, 14, 15], an alternative
method was added to detect whether this lesion
expressed somatostatin receptors. Thus SPECT/CT or
positron emission tomography/computed tomography
(PET/CT) imaging with somatostatin analog radiotracers
are highly effective methods for detection of meningi-
omas [6–13].
In accordance with a few studies on ONSMs [6, 7], the
case reported herein showed an intense uptake of
[111In]-pentetreotide in the last third of the intraorbital
right optic nerve (Fig. 1c, d, g and h), as well as physio-
logical pituitary uptake (Fig. 1c and d). This radiotracer
presents a very high affinity for somatostatin receptor
subtype 2 with high sensitivity and specificity, as well as
[111In]-octreotide. There have also been reports on using
somatostatin to treat intracranial meningiomas and
monitor the efficacy of the treatment [16].
Consequently, this imaging technique provides good
proof so that the exact origin of certain optic nerve tu-
mors can be identified, especially and specifically in
cases of very small tumors, in order to avoid biopsy and
give the best treatment available quickly. In the majority
of ONSMs involving the orbit, complete surgical resec-
tion is not possible and the results of surgical decom-
pression are poor, despite the natural progression of
diseases with progressive visual loss [15]. The diagnosis
of ONSM is a crucial one, because modern surgical and/or
radiotherapy approaches at an early stage may allow total
resection and improve the chances of preserving vi-
sion [14, 15, 17–19]. For this reason, our patient
could be treated with the best adapted procedure,
resulting in better visual acuity. This technique with
multimodal imaging provided positive identification
rapidly, and our patient was spared more permanent
visual damage or intracranial growth. A surgical ap-
proach was not adapted and presented a risk in this
case due to the location and the small size.
This case supports other studies [6, 7] that have demon-
strated a high [111In]-pentetreotide uptake by ONSMs,
and shows the importance of making an early and
noninvasive diagnosis compared to other orbital le-
sions, that is, optic nerve gliomas, optic nerve inflam-
mation, non-Hodgkin lymphomas, vascular lesions,
and sarcoidosis [2, 3]. In the present case, it was the
most effective method to reverse the initial diagnosis
of optic neuritis.
Conclusions
In the diagnosis of ONSMs, somatostatin receptor sub-
type 2 detected with [111In]-pentetreotide SPECT/CT
fused on MRI is a valuable additional tool, optimizing
the diagnosis and obviating the need for a more invasive
procedure.
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